Physician profile
Mahendra K Gupta
NPI 1508899139
$95,517.62
in general payments reported to CMS, 2019-2025
16 companies · $8,174 in 2025
The $8,174 reported for 2025 was more than what 87% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $38K · 2020: $15K · 2021: $20K · 2022: $2,863 · 2023: $5,710 · 2024: $4,673 · 2025: $8,174.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $14K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,000 · Travel and Lodging: $1,738 · Food and Beverage: $389 · Honoraria: $200 · Education: $52.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $14,177.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,000.00 |
| Travel and Lodging | $1,738.35 |
| Food and Beverage | $389.45 |
| Honoraria | $200.00 |
| Education | $52.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $28,598.98 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $17,681.23 | 2020-2025 | Imfinzi, Tagrisso |
| Amgen INC. | $14,666.66 | 2019-2020 | |
| Incyte Corporation | $13,073.27 | 2020-2021 | |
| Jazz Pharmaceuticals INC. | $11,422.00 | 2020-2021 | |
| Avyxa Pharma, LLC | $3,368.93 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $3,089.56 | 2019-2025 | |
| Janssen Biotech, INC. | $1,350.00 | 2023 | |
| Genentech USA, INC. | $1,137.50 | 2021 | |
| Daiichi Sankyo INC. | $725.00 | 2023-2024 | Enhertu |
| Athenex Pharmaceutical Division, LLC | $175.00 | 2020 | |
| Blue Earth Diagnostics | $72.61 | 2019 | |
| Progenics Pharmaceuticals, INC. | $64.03 | 2022 | |
| Pfizer INC. | $52.00 | 2025 | |
| Tempus Ai, INC | $28.93 | 2024 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mahendra Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.